Food Safety Incidents

Suggestion of therapeutic properties has been detected in Mini shape dietary supplement.

Written by SGS Digicomply Editorial Team | Feb 27, 2026 11:00:00 PM

Incident Report on Dietary Supplement

On February 12, 2026, a significant food safety incident was reported concerning a dietary supplement identified as a "Mini shape dietary supplement." This incident originated in Brazil and was highlighted by the Brazilian Health Regulatory Agency, known as ANVISA.

The primary concern surrounding this product is the suggestion of therapeutic properties that have been detected. Such claims can pose serious risks to consumers, as dietary supplements are often not subjected to the same rigorous testing and regulatory standards as pharmaceuticals. The presence of unverified therapeutic claims can lead to misuse or over-reliance on the product for health benefits that may not be substantiated by scientific evidence.

Consumers are advised to exercise caution when considering dietary supplements that claim to offer therapeutic effects. It is essential to consult healthcare professionals before starting any new supplement regimen, especially those that make bold health claims.

Regulatory bodies like ANVISA play a crucial role in monitoring and ensuring the safety of dietary supplements. It is vital for consumers to stay informed about the products they consume and to report any adverse effects or concerns regarding dietary supplements to the appropriate authorities.

In conclusion, the detection of unverified therapeutic properties in the Mini shape dietary supplement raises important food safety concerns that warrant attention from both consumers and regulatory agencies.

  • Incident: Suggestion of therapeutic properties has been detected in Mini shape dietary supplement.
  • Date: 2026-02-12
  • Product: Mini shape dietary supplement
  • Market: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
  • Origin of issue: Brazil
  • Hazard: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
  • Incident Category: Control
  • Source: Brazilian Health Regulatory Agency - ANVISA